This week Life Science Cares Boston launched a Health Equity Portfolio Co-Investment Program as part of its Anti-Poverty Strategy for Greater Boston. We are proud that our foundation is able to support LSC’s new grantmaking program aimed at addressing health inequities among low-income families and communities in the area. Learn more: https://bit.ly/4aMDXnJ #lifesciences #giveback #antipoverty
K2 HealthVentures
Venture Capital and Private Equity Principals
Boston, Massachusetts 884 followers
K2 HealthVentures provides venture debt and equity capital to private and public life science & healthcare companies.
About us
K2 HealthVentures (K2HV) is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. We are healthcare specialists with deep domain expertise, and we understand both the opportunities and challenges that face venture-stage and growth-stage companies. Further, our flat organizational set-up enables nimble decision-making, and our evergreen fund structure allows us to be creative and adapt our facilities to a company’s specific needs over both the short and the long term. Over the last 4 years we have committed more than $1 billion in debt and equity capital to both private and public companies, and our team’s track record spans decades of investing in and supporting innovative life sciences and healthcare companies (with over $4 billion total investments in over 100 portfolio companies).
- Website
-
https://k2hv.com/
External link for K2 HealthVentures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Biotechnology, Medical Devices, Healthcare, Venture Debt, Venture Capital, and Specialty Finance
Locations
-
Primary
Get directions
855 Boylston St
10th Floor
Boston, Massachusetts 02116, US
-
Get directions
375 Park Ave
22nd Floor
New York, NY 10152, US
Employees at K2 HealthVentures
Updates
-
Earlier this week K2HV attended Life Science Cares Boston’s Impact Breakfast & was awarded the Luke Timmerman Impact Award. Our team is honored to have received this recognition. In Parag Shah’s words, “We are up here being recognized because we notice the inequities that are out there, and we are fortunate to be able to give from our abundance, to give a little bit back.” As an anchor investor in Life Science Cares’ new Health Equity initiative, we are grateful to all those joining in our efforts to improve health equity & thank you Luke Timmerman for the honor.
-
-
K2 HealthVentures reposted this
Thrilled to share our recent feature on NBC NEWS! 🌟 Explore the rise of Prescribed Pediatric Extended Care Centers (PPECs), or 'medical daycares,' across the U.S. These centers provide a haven for children with complex medical conditions, offering normalcy, play, and interaction under the watchful care of dedicated nurses. Spark Pediatrics is proud to be part of this positive movement, ensuring a nurturing environment for every child in our care. Watch the story here: https://lnkd.in/gtiijABX #PediatricCare #MedicalDaycare #NBCNewsFeature #SparkPediatrics
'Medical daycares' on the rise in the U.S.
https://www.youtube.com/
-
K2 HealthVentures reposted this
As we enter 2024, our team would like to reflect on K2HV’s progress and accomplishments. Learn more in our Year End Letter:
K2HV Year End Update
K2 HealthVentures on LinkedIn
-
As we enter 2024, our team would like to reflect on K2HV’s progress and accomplishments. Learn more in our Year End Letter:
K2HV Year End Update
K2 HealthVentures on LinkedIn
-
Today we are thrilled to announce our partnership with new portfolio company Acumen Pharmaceuticals, Inc., a clinical-stage drug development company focused on developing a novel therapeutic for #AlzheimersDisease, including ACU193, an investigational humanized monoclonal antibody that selectively targets toxic soluble amyloid-beta oligomers (AβOs). This $50M loan agreement will provide additional operational flexibility and will help fund, among other activities, Acumen’s development program for a subcutaneous form of ACU193. Our collaboration further demonstrates K2HV’s ability to finance life sciences companies through multiple stages of development, and we look forward to supporting Acumen’s leadership team in realizing their mission of creating a potential best-in-class treatment for Alzheimer’s Disease. Read more: https://k2hv.com/news
News — K2 Health Ventures
k2hv.com
-
Today we are thrilled to partner with new portfolio company MindMed on a $50M credit facility to advance their portfolio of product candidates across an array of disorders of the brain where there are significant unmet medical needs. With $15M drawn at loan closing, this financing enhances MindMed’s operational and strategic flexibility through multiple clinical catalysts on MM-120 and MM-402 product candidates. K2HV’s investment in MindMed further demonstrates our ability to finance life sciences companies through multiple stages of development and in emerging areas of the drug development ecosystem that hold great promise for patients. Read more: bit.ly/3qyHyVx
-
-
We’re #hiring a new Finance and Accounting Manager in Boston, Massachusetts. Apply today or share this post with your network.